scholarly journals Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open-label, phase 2 study

2017 ◽  
Vol 35 ◽  
pp. 211-212
Author(s):  
G.P. Collins ◽  
A. Noy ◽  
S. de Vos ◽  
C. Thieblemont ◽  
P. Martin ◽  
...  
Keyword(s):  
Marginal Zone ◽  
Single Agent ◽  
Marginal Zone Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Safety And Efficacy ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

2011 ◽  
Vol 17 (21) ◽  
pp. 6905-6913 ◽  
Author(s):  
Richard S. Finn ◽  
Carmelo Bengala ◽  
Nuhad Ibrahim ◽  
Henri Roché ◽  
Joseph Sparano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Single Agent ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

Abstract #1219 Open-Label Phase 2 Study to Assess Safety and Efficacy Of Relacorilant (Cort125134), A Selective Cortisol Modulator, in the Treatment of Endogenous Hypercortisolism

2018 ◽  
Vol 24 ◽  
pp. 314-315
Author(s):  
Andreas Moraitis ◽  
Nidhi Agrawal ◽  
Irina Bancos ◽  
Francesco Celi ◽  
Murray Gordon ◽  
...  
Keyword(s):  
Phase 2 ◽  
Open Label ◽  
Safety And Efficacy ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
J. Trotman ◽  
A. Tedeschi ◽  
K. Linton ◽  
P. McKay ◽  
B. Hu ◽  
...  
Keyword(s):  
Marginal Zone ◽  
Marginal Zone Lymphoma ◽  
Phase 2 ◽  
Safety And Efficacy ◽  
Phase 2 Study

scholarly journals Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

2019 ◽  
Vol 185 (5) ◽  
pp. 874-882 ◽  
Author(s):  
Melody R. Becnel ◽  
Loretta J. Nastoupil ◽  
Felipe Samaniego ◽  
Richard E. Davis ◽  
M. J. You ◽  
...  
Keyword(s):  
Subgroup Analysis ◽  
Marginal Zone ◽  
Marginal Zone Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase ◽  
Long Term Follow Up

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document